Martin Puchwein, country president for Novartis Group Czech Republic, and general manager for pharma, shares his perspectives on launching innovative drugs in the country, including some new therapeutic approaches such as cell and gene therapies. Puchwein also discusses Novartis’ ambition to transform its corporate culture towards becoming an organization where people are curious, inspired and unbossed. Finally, he stresses the strategic significance of the Czech Republic for the group as the location of one of its Global Service Centers, as well as the country’s large contribution to the clinical development of new drugs.
The Czech Republic is joining other advanced economies in Europe in terms of economic development but also healthcare standards
